Literature DB >> 28439528

Foveal thinning in neuromyelitis optica: A sign of retinal astrocytopathy?

Takashi Yamamura1, Ichiro Nakashima1.   

Abstract

Entities:  

Year:  2017        PMID: 28439528      PMCID: PMC5395067          DOI: 10.1212/NXI.0000000000000347

Source DB:  PubMed          Journal:  Neurol Neuroimmunol Neuroinflamm        ISSN: 2332-7812


× No keyword cloud information.
Patients with neuromyelitis optica spectrum disorder (NMOSD) typically manifest recurrent episodes of optic neuritis (ON) and myelitis. Recently revised diagnostic criteria[1] do not restrict the diagnosis of NMOSD to patients associated with elevation of anti–aquaporin 4 antibody (AQP4Ab), capable of causing destruction of astrocytes expressing AQP4. If compatible clinical and radiologic features are present, the diagnosis of NMOSD is given to patients with autoantibodies (Ab) specific for myelin oligodendrocyte glycoprotein (MOG).[2] However, compared with MOGAb+ NMOSD, clinical relapses tend to be more serious in AQP4Ab+ patients and could result in devastating neurologic sequelae manifested by blindness, paralysis, cognitive dysfunction, or neurogenic pain. While acute relapses are characteristic of the relapsing-remitting form of MS, insidious worsening related to chronic neuroinflammation is the basis for the diagnosis of secondary progressive MS. Although secondary progressive disease was assumed to be uncommon in NMOSD,[3] recent studies relying on MRI findings have described progressive brain or spinal cord atrophy[4,5] without a sign of relapses in patients with AQP4Ab+ NMOSD. In this issue of Neurology® Neuroimmunology & Neuroinflammation, Oertel et al.[6] measured the foveal thickness and the thickness of surrounding structures (peripapillary retinal nerve fiber layer and ganglion cell and inner plexiform layers) in patients with NMOSD using optical coherence tomography (OCT). They compared eyes from patients who had long extensive spinal cord lesions archetypal for NMOSD but no history of ON with eyes from NMOSD patients with history of ON and eyes from healthy controls. In parallel, diffusion tensor imaging (DTI) was used to evaluate the microstructural changes in the optic radiation, which is responsible for transmitting visual signals from the retina to the visual cortex. The authors demonstrate that central foveal thickness is significantly reduced in the eyes of the 6 patients without a history of ON as compared to controls, although high-contrast visual acuity of these patients was normal. Fovea is a tiny pit in the macula of the retina and is responsible for the central, high-resolution color vision. As the fovea is enriched in Müller cells expressing AQP4, their observation suggests the occurrence of primary retinal astrocytopathy in NMOSD. DTI analysis also showed secondary microstructural changes in the afferent visual system in parallel with the foveal thinning. Shortly before this publication,[6] OCT was applied by Korean and Japanese groups for the analysis of retinal changes in patients with NMOSD.[7,8] Notably, the Korean study also showed the presence of foveal thinning in the retina of unaffected eyes of patients with NMOSD. Moreover, the foveal thinning was correlated with a reduction in low-contrast visual acuity in the Korean study, implying that the retina of the “unaffected eyes” in AQP4Ab+ NMOSD might be actually damaged by chronic autoimmune inflammation targeting Müller cells or retinal astrocytes. One could say that prevention of relapses is a goal of therapy for NMOSD, assuming that only serious relapses are thought to cause neurologic sequelae. However, the presence of retinal changes without previous ON indicates that an insidious development of pathology cannot be ignored in patients with NMOSD. Given that the life expectancy of patients with NMOSD has substantially improved, the future goal of therapy should not only be prevention of relapses, but prevention of new lesion development by immunotherapy under close monitoring. Alterations in Müller cells have been also described in a rodent model of NMOSD.[9] This pathology was dependent on both AQP4Ab and T cells, indicating the importance of T-cell control to achieve good control of NMOSD. It is known that the shape and size of retinal fovea evaluated by OCT differ among different ethnic groups. In this regard, data from both Caucasian and Asian patients are precious and useful. The size of the avascular area in the fovea may influence OCT evaluation.[10] Therefore, future studies should evaluate the avascular area as well. The study by Oertel et al.[6] together with recent publications from other investigators[7,8] have begun to stimulate discussion about the goal of therapy in patients with NMOSD regarding the prognosis of visual function. However, it is too early to make any conclusion until the reproducibility of the results is confirmed in prospective studies involving more patients.
  10 in total

1.  Progressive cerebral atrophy in neuromyelitis optica.

Authors:  Yoko Warabi; Toshiyuki Takahashi; Eiji Isozaki
Journal:  Mult Scler       Date:  2015-09-10       Impact factor: 6.312

2.  A secondary progressive clinical course is uncommon in neuromyelitis optica.

Authors:  D M Wingerchuk; S J Pittock; C F Lucchinetti; V A Lennon; B G Weinshenker
Journal:  Neurology       Date:  2007-02-20       Impact factor: 9.910

3.  Severe demyelination but no astrocytopathy in clinically definite neuromyelitis optica with anti-myelin-oligodendrocyte glycoprotein antibody.

Authors:  Kensuke Ikeda; Naoki Kiyota; Hiroshi Kuroda; Douglas Kazutoshi Sato; Shuhei Nishiyama; Toshiyuki Takahashi; Tatsuro Misu; Ichiro Nakashima; Kazuo Fujihara; Masashi Aoki
Journal:  Mult Scler       Date:  2014-09-25       Impact factor: 6.312

4.  Foveal shape and structure in a normal population.

Authors:  Sarah Tick; Florence Rossant; Itebeddine Ghorbel; Alain Gaudric; José-Alain Sahel; Philippe Chaumet-Riffaud; Michel Paques
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-07-29       Impact factor: 4.799

5.  Subclinical primary retinal pathology in neuromyelitis optica spectrum disorder.

Authors:  In Hye Jeong; Ho Jin Kim; Nam-Hee Kim; Kyoung Sook Jeong; Choul Yong Park
Journal:  J Neurol       Date:  2016-05-03       Impact factor: 4.849

6.  International consensus diagnostic criteria for neuromyelitis optica spectrum disorders.

Authors:  Dean M Wingerchuk; Brenda Banwell; Jeffrey L Bennett; Philippe Cabre; William Carroll; Tanuja Chitnis; Jérôme de Seze; Kazuo Fujihara; Benjamin Greenberg; Anu Jacob; Sven Jarius; Marco Lana-Peixoto; Michael Levy; Jack H Simon; Silvia Tenembaum; Anthony L Traboulsee; Patrick Waters; Kay E Wellik; Brian G Weinshenker
Journal:  Neurology       Date:  2015-06-19       Impact factor: 9.910

7.  Impact of the anti-aquaporin-4 autoantibody on inner retinal structure, function and structure-function associations in Japanese patients with optic neuritis.

Authors:  Yoshiko Matsumoto; Sotaro Mori; Kaori Ueda; Takuji Kurimoto; Akiyasu Kanamori; Yuko Yamada; Ichiro Nakashima; Makoto Nakamura
Journal:  PLoS One       Date:  2017-02-15       Impact factor: 3.240

8.  Microstructural visual system changes in AQP4-antibody-seropositive NMOSD.

Authors:  Frederike C Oertel; Joseph Kuchling; Hanna Zimmermann; Claudia Chien; Felix Schmidt; Benjamin Knier; Judith Bellmann-Strobl; Thomas Korn; Michael Scheel; Alexander Klistorner; Klemens Ruprecht; Friedemann Paul; Alexander U Brandt
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2017-02-22

9.  Cervical spinal cord atrophy in NMOSD without a history of myelitis or MRI-visible lesions.

Authors:  Rachel E Ventura; Ilya Kister; Sohae Chung; James S Babb; Timothy M Shepherd
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2016-04-14

10.  Aquaporin 4-specific T cells and NMO-IgG cause primary retinal damage in experimental NMO/SD.

Authors:  Bleranda Zeka; Maria Hastermann; Nathalie Kaufmann; Kathrin Schanda; Marko Pende; Tatsuro Misu; Paulus Rommer; Kazuo Fujihara; Ichiro Nakashima; Charlotte Dahle; Fritz Leutmezer; Markus Reindl; Hans Lassmann; Monika Bradl
Journal:  Acta Neuropathol Commun       Date:  2016-08-08       Impact factor: 7.801

  10 in total
  12 in total

Review 1.  [Optical coherence tomography in neuromyelitis optica spectrum disorders].

Authors:  F C Oertel; H Zimmermann; A U Brandt; F Paul
Journal:  Nervenarzt       Date:  2017-12       Impact factor: 1.214

Review 2.  The Contribution of Optical Coherence Tomography in Neuromyelitis Optica Spectrum Disorders.

Authors:  Javier Mateo; Olivia Esteban; Mireya Martínez; Andrzej Grzybowski; Francisco Javier Ascaso
Journal:  Front Neurol       Date:  2017-09-29       Impact factor: 4.003

Review 3.  Optical coherence tomography in neuromyelitis optica spectrum disorders: potential advantages for individualized monitoring of progression and therapy.

Authors:  Frederike C Oertel; Hanna Zimmermann; Friedemann Paul; Alexander U Brandt
Journal:  EPMA J       Date:  2017-12-22       Impact factor: 6.543

Review 4.  Mechanisms for lesion localization in neuromyelitis optica spectrum disorders.

Authors:  Monika Bradl; Markus Reindl; Hans Lassmann
Journal:  Curr Opin Neurol       Date:  2018-06       Impact factor: 5.710

5.  Differences in clinical features between optic neuritis in neuromyelitis optica spectrum disorders and in multiple sclerosis.

Authors:  Jindapa Srikajon; Sasitorn Siritho; Chanon Ngamsombat; Naraporn Prayoonwiwat; Niphon Chirapapaisan
Journal:  Mult Scler J Exp Transl Clin       Date:  2018-08-11

Review 6.  Diagnosis and Treatment of NMO Spectrum Disorder and MOG-Encephalomyelitis.

Authors:  Nadja Borisow; Masahiro Mori; Satoshi Kuwabara; Michael Scheel; Friedemann Paul
Journal:  Front Neurol       Date:  2018-10-23       Impact factor: 4.003

7.  Peripapillary and parafoveal vascular network assessment by optical coherence tomography angiography in aquaporin-4 antibody-positive neuromyelitis optica spectrum disorders.

Authors:  Yongheng Huang; Lei Zhou; Jingzi ZhangBao; Tongjia Cai; Bei Wang; Xiaoyang Li; Liang Wang; Chuanzhen Lu; Chongbo Zhao; Jiahong Lu; Chao Quan; Min Wang
Journal:  Br J Ophthalmol       Date:  2018-07-18       Impact factor: 4.638

8.  Association Between BDNF Val66Met Polymorphism and Optic Neuritis Damage in Neuromyelitis Optica Spectrum Disorder.

Authors:  Ting Shen; Vivek Gupta; Con Yiannikas; Alexander Klistorner; Stuart L Graham; Yuyi You
Journal:  Front Neurosci       Date:  2019-11-19       Impact factor: 4.677

9.  Precision in neuroimmunology.

Authors:  Josep Dalmau
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2017-04-11

Review 10.  Cognitive impairment in NMOSD-More questions than answers.

Authors:  Dominika Czarnecka; Magdalena Oset; Iwona Karlińska; Mariusz Stasiołek
Journal:  Brain Behav       Date:  2020-10-06       Impact factor: 2.708

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.